Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Osteoarthritis Cartilage. 2015 Dec 31;24(5):776–785. doi: 10.1016/j.joca.2015.12.011

Figure 2. Cost-effectiveness of Adding Tanezumab by Starting Pain, Cost, and Mode of Administration.

Figure 2

This figure shows the incremental cost-effectiveness ratios (ICERs) associated with adding Tanezumab to the standard of care. Lighter yellows indicate higher value, while darker reds indicate lower value. The results are stratified by starting WOMAC pain severity (0 – 100 scale, 100 = worst) and the cost of the drug and its delivery, assuming doses are delivered every 8 weeks. Mean WOMAC pain severity was 67 for high pain, 45 for medium pain, and 35 for low pain. These results all follow the base case assumption of a 1% incidence of rapid OA progression in the first year of treatment and 0.5% in subsequent years, where rapid OA progression requires immediate joint replacement with a lower than normal efficacy.